Alexandra Balcom Nuvalent, Inc. (NUVL) insider trading activity

Alexandra Balcom is Chief Financial Officer of Nuvalent, Inc.. Currently has a direct ownership of 61,734 shares of NUVL, which is worth approximately $5.09 Million. The most recent transaction as insider was on Jul 16, 2025, when has been sold 14,700 shares (Class A Common Stock) at a price of $85.1 per share, resulting in proceeds of $1,250,970. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 61.7K

0% 3M change

85.39% 12M change

Total Value Held $5.09 Million

Alexandra Balcom Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 16 2025	SELL Open market or private sale	$1,250,970 $85.1 p/Share	14,700 Reduced 19.23%	61,734 Class A Common Stock
Jul 16 2025	BUY Exercise of conversion of derivative security	$278,271 $18.93 p/Share	14,700 Added 16.13%	76,434 Class A Common Stock
Jul 15 2025	SELL Open market or private sale	$446,419 $84.23 p/Share	5,300 Reduced 7.91%	61,734 Class A Common Stock
Jul 15 2025	BUY Exercise of conversion of derivative security	$100,329 $18.93 p/Share	5,300 Added 7.33%	67,034 Class A Common Stock
Jun 27 2025	SELL Open market or private sale	$1,600,400 $80.02 p/Share	20,000 Reduced 24.47%	61,734 Class A Common Stock
Jun 27 2025	BUY Exercise of conversion of derivative security	$378,600 $18.93 p/Share	20,000 Added 19.66%	81,734 Class A Common Stock
Jan 06 2025	SELL Open market or private sale	$318,790 $79.38 p/Share	4,016 Reduced 6.11%	61,734 Class A Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	18,750 Added 22.19%	65,750 Class A Common Stock
Dec 17 2024	BUY Exercise of conversion of derivative security	$54,663 $3.99 p/Share	13,700 Added 22.57%	47,000 Class A Common Stock
Nov 29 2024	SELL Open market or private sale	$959,700 $95.97 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Nov 29 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Oct 31 2024	SELL Open market or private sale	$896,700 $89.67 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Oct 31 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Sep 30 2024	SELL Open market or private sale	$1,005,000 $100.5 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Sep 30 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Aug 30 2024	SELL Open market or private sale	$847,900 $84.79 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Aug 30 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Jul 31 2024	SELL Open market or private sale	$792,400 $79.24 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Jul 31 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Jun 28 2024	SELL Open market or private sale	$760,200 $76.02 p/Share	10,000 Reduced 23.09%	33,300 Class A Common Stock
Jun 28 2024	BUY Exercise of conversion of derivative security	$278,500 $27.85 p/Share	10,000 Added 18.76%	43,300 Class A Common Stock
Jan 05 2024	BUY Grant, award, or other acquisition	-	33,300 Added 50.0%	33,300 Class A Common Stock
Dec 18 2023	SELL Open market or private sale	$2,274,600 $75.82 p/Share	30,000 Reduced 100.0%	0 Class A Common Stock
Dec 18 2023	BUY Exercise of conversion of derivative security	$32,400 $1.08 p/Share	30,000 Added 50.0%	30,000 Class A Common Stock
Jul 31 2023	SELL Open market or private sale	$1,226,250 $49.05 p/Share	25,000 Reduced 100.0%	0 Class A Common Stock

Also insider at

GLYC

GLYCOMIMETICS INC Healthcare

Director